Expand access to neuroplastogen treatments such as ibogaine for veterans.

Michael T. McCaul · Texas · Republican

policy impact 0.62 specificity 0.78 extraction confidence 86%

Commitment kind: unknown. Promised action: not established. Promised outcome: not established. Deadline: unknown; not assumed expired.

Contest this claim

Occurrences

Evidence

legacy_unverified · Source version not recorded · locator unknown

H.R. 9559 was introduced by Mr. Luttrell "for himself, Mr. McCaul, Mr. Bergman, and Mr. Correa" and is titled the IBOGAINE Act. The bill would accelerate development of and access to psychedelic drugs, define ibogaine, create Schedule I Right to Try registration procedures, direct rescheduling review for ibogaine, and require VA planning and reporting on emerging therapeutic interventions.

Unverified model/legacy excerpt; not proof. AI summary (separate from source): McCaul took concrete federal legislative action by joining introduction of a bill aimed at expanding access pathways for ibogaine and other psychedelic/neuroplastogen treatments, including VA implementation planning. The bill was only introduced/referred, so it does not show full delivery by itself.

unresolved same_term A for effort

H.R. 9559 (IH) - Initiating Biomedical Outcomes to Garner Advancements into Innovative Neuroplastogen Efficacy Act
secondary · model gpt-5.5 · confidence 90%

Contest this evidence item

legacy_unverified · Source version not recorded · locator unknown

HHS and VA entered an MOU to coordinate research, clinical development, and responsible deployment of future FDA-approved psychedelic drug products for veterans. Actions include increasing veteran clinical research participation, clinician training, data sharing, FDA coordination, NIDA ibogaine research support, and ARPA-H funding competition for ibogaine research.

Unverified model/legacy excerpt; not proof. AI summary (separate from source): Federal agencies have taken concrete steps that partially expand access through research, trial participation, workforce preparation, and future FDA pathways, but the source frames deployment as future and FDA-dependent rather than current routine VA treatment access.

partial same_term A for effort

HHS & VA Announce Bold, Comprehensive Partnership to Advance Rapid-Acting Mental Health Treatments for Veterans
secondary · model gpt-5.5 · confidence 88%

Contest this evidence item

Assessments

Public state: unverified As of unknown · legacy_unverified · . Original AI recommendation (not independently established): partial. same_term A for effort

McCaul materially supported a federal legislative pathway by joining introduction of H.R. 9559, the IBOGAINE Act, which aimed to accelerate development of and access to ibogaine and related neuroplastogen therapies for veterans. Separately, HHS and VA took same-term agency steps toward research participation, clinician preparation, data sharing, FDA coordination, and ibogaine research funding. However, the evidence shows future FDA-dependent deployment and research access rather than current broad treatment access for veterans, and McCaul's bill had not passed. This supports partial fulfillment, not full delivery.

provider codex_cli · model gpt-5.5 · confidence 86%